NANOV Stock Overview
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway.
Nordic Nanovector Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr10.72|
|52 Week High||kr33.80|
|52 Week Low||kr10.58|
|1 Month Change||-23.54%|
|3 Month Change||-18.04%|
|1 Year Change||-57.53%|
|3 Year Change||-74.02%|
|5 Year Change||-88.89%|
|Change since IPO||-61.71%|
Recent News & Updates
|NANOV||NO Biotechs||NO Market|
Return vs Industry: NANOV underperformed the Norwegian Biotechs industry which returned -48.9% over the past year.
Return vs Market: NANOV underperformed the Norwegian Market which returned 12.6% over the past year.
|NANOV Average Weekly Movement||10.0%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||7.4%|
|10% most volatile stocks in NO Market||12.4%|
|10% least volatile stocks in NO Market||4.2%|
Stable Share Price: NANOV is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: NANOV's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company’s lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia.
Nordic Nanovector Fundamentals Summary
|NANOV fundamental statistics|
Is NANOV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NANOV income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 20, 2022
|Earnings per share (EPS)||-3.83|
|Net Profit Margin||0.00%|
How did NANOV perform over the long term?See historical performance and comparison
Is Nordic Nanovector undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NANOV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NANOV's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NANOV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: NANOV is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NANOV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NANOV is overvalued based on its PB Ratio (4.6x) compared to the NO Biotechs industry average (3.9x).
How is Nordic Nanovector forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NANOV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NANOV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NANOV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NANOV is forecast to have no revenue next year.
High Growth Revenue: NANOV is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NANOV's Return on Equity is forecast to be high in 3 years time
How has Nordic Nanovector performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NANOV is currently unprofitable.
Growing Profit Margin: NANOV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NANOV is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare NANOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NANOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-5.2%).
Return on Equity
High ROE: NANOV has a negative Return on Equity (-163.87%), as it is currently unprofitable.
How is Nordic Nanovector's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NANOV's short term assets (NOK376.4M) exceed its short term liabilities (NOK103.8M).
Long Term Liabilities: NANOV's short term assets (NOK376.4M) exceed its long term liabilities (NOK4.4M).
Debt to Equity History and Analysis
Debt Level: NANOV is debt free.
Reducing Debt: NANOV has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NANOV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NANOV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.9% each year
What is Nordic Nanovector current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NANOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NANOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NANOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NANOV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NANOV has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Erik Skullerud (52 yo)
Mr. Erik Skullerud is Chief Executive Officer of Nordic Nanovector ASA from September 20, 2021. Mr. Skullerud joins the Company from Element Consulting GmbH, a globally focused boutique advisory and consul...
CEO Compensation Analysis
Compensation vs Market: Erik's total compensation ($USD597.83K) is above average for companies of similar size in the Norwegian market ($USD330.08K).
Compensation vs Earnings: Insufficient data to compare Erik's compensation with company performance.
Experienced Management: NANOV's management team is considered experienced (2.4 years average tenure).
Experienced Board: NANOV's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.
Nordic Nanovector ASA's employee growth, exchange listings and data sources
- Name: Nordic Nanovector ASA
- Ticker: NANOV
- Exchange: OB
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr1.281b
- Shares outstanding: 116.04m
- Website: https://www.nordicnanovector.com
Number of Employees
- Nordic Nanovector ASA
- KjelsAsveien 168 B
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.